Targeting D-Amino Acid Oxidase (DAAO) for the Treatment of Schizophrenia: Rationale and Current Status of Research

Overview

Journal CNS Drugs

Specialties Neurology
Pharmacology

Date 2022 Oct 4

PMID 36194364

Authors

Chien-Yi Kuo

Chieh-Hsin Lin

Hsien-Yuan Lane

Affiliations

Soon will be listed here.

Abstract

In the brain, D-amino acid oxidase (DAAO) is a peroxisomal flavoenzyme. Through oxidative deamination by DAAO, D-serine, the main coagonist of synaptic N-methyl-D-aspartate receptors (NMDARs), is degraded into α-keto acids and ammonia; flavin adenine dinucleotide (FAD) is simultaneously reduced to dihydroflavine-adenine dinucleotide (FADH2), which is subsequently reoxidized to FAD, with hydrogen peroxide produced as a byproduct. NMDAR hypofunction is implicated in the pathogenesis of schizophrenia. In previous studies, compared with control subjects, patients with schizophrenia had lower D-serine levels in peripheral blood and cerebrospinal fluid but higher DAAO expression and activity in the brain. Inhibiting DAAO activity and slowing D-serine degradation by using DAAO inhibitors to enhance NMDAR function may be a new strategy for use in the treatment of schizophrenia. The aim of this leading article is to review the current research in DAAO inhibitors.

Citing Articles

Interpretable machine learning to evaluate relationships between DAO/DAOA (pLG72) protein data and features in clinical assessments, functional outcome, and cognitive function in schizophrenia patients.

Lin C, Lin E, Lane H Schizophrenia (Heidelb). 2025; 11(1):27.

PMID: 39987274 PMC: 11846841. DOI: 10.1038/s41537-024-00548-z.

Variations of blood D-serine and D-aspartate homeostasis track psychosis stages.

Rampino A, Garofalo M, Nuzzo T, Favia M, Saltarelli S, Masellis R Schizophrenia (Heidelb). 2024; 10(1):115.

PMID: 39702391 PMC: 11659589. DOI: 10.1038/s41537-024-00537-2.

DAAO Mutant Sites among Different Mice Strains and Their Effects on Enzyme Activity.

Yu-Cong Z, Sheng-Ling F, Hao L Protein J. 2024; 44(1):102-112.

PMID: 39487887 DOI: 10.1007/s10930-024-10235-8.

Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways.

Zhang T, Liu C, Zhong N, Wang Y, Huang Y, Zhang X Int J Mol Sci. 2024; 25(19).

PMID: 39408997 PMC: 11477438. DOI: 10.3390/ijms251910668.

Advances and challenges in serine in the central nervous system: physicochemistry, physiology, and pharmacology.

Li J, Bai Y, Zhang S Metab Brain Dis. 2024; 39(8):1637-1647.

PMID: 39186223 DOI: 10.1007/s11011-024-01418-4.

References

Lewis D, Lieberman J . Catching up on schizophrenia: natural history and neurobiology. Neuron. 2001; 28(2):325-34. DOI: 10.1016/s0896-6273(00)00111-2. View

Green M, Schooler N, Kern R, Frese F, Granberry W, Harvey P . Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. Am J Psychiatry. 2011; 168(4):400-7. DOI: 10.1176/appi.ajp.2010.10030414. View

Lin C, Huang C, Chang Y, Chen P, Lin C, Tsai G . Clinical symptoms, mainly negative symptoms, mediate the influence of neurocognition and social cognition on functional outcome of schizophrenia. Schizophr Res. 2013; 146(1-3):231-7. DOI: 10.1016/j.schres.2013.02.009. View

Iyo M, Tadokoro S, Kanahara N, Hashimoto T, Niitsu T, Watanabe H . Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J Clin Psychopharmacol. 2013; 33(3):398-404. DOI: 10.1097/JCP.0b013e31828ea95c. View

Coyle J . NMDA receptor and schizophrenia: a brief history. Schizophr Bull. 2012; 38(5):920-6. PMC: 3446237. DOI: 10.1093/schbul/sbs076. View

Kantrowitz J, Javitt D . N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?. Brain Res Bull. 2010; 83(3-4):108-21. PMC: 2941541. DOI: 10.1016/j.brainresbull.2010.04.006. View

Lin C, Lane H . Early Identification and Intervention of Schizophrenia: Insight From Hypotheses of Glutamate Dysfunction and Oxidative Stress. Front Psychiatry. 2019; 10:93. PMC: 6400883. DOI: 10.3389/fpsyt.2019.00093. View

Verrall L, Burnet P, Betts J, Harrison P . The neurobiology of D-amino acid oxidase and its involvement in schizophrenia. Mol Psychiatry. 2009; 15(2):122-37. PMC: 2811712. DOI: 10.1038/mp.2009.99. View

Coyle J . Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol. 2006; 26(4-6):365-84. PMC: 11881825. DOI: 10.1007/s10571-006-9062-8. View

10.

Krystal J, Karper L, Seibyl J, Freeman G, Delaney R, Bremner J . Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994; 51(3):199-214. DOI: 10.1001/archpsyc.1994.03950030035004. View

11.

Mohn A, Gainetdinov R, Caron M, Koller B . Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell. 1999; 98(4):427-36. DOI: 10.1016/s0092-8674(00)81972-8. View

12.

Trubetskoy V, Pardinas A, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli T . Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature. 2022; 604(7906):502-508. PMC: 9392466. DOI: 10.1038/s41586-022-04434-5. View

13.

Nakazawa K, Sapkota K . The origin of NMDA receptor hypofunction in schizophrenia. Pharmacol Ther. 2019; 205:107426. PMC: 6981256. DOI: 10.1016/j.pharmthera.2019.107426. View

14.

Fuchs S, Berger R, Klomp L, De Koning T . D-amino acids in the central nervous system in health and disease. Mol Genet Metab. 2005; 85(3):168-80. DOI: 10.1016/j.ymgme.2005.03.003. View

15.

Price G, Ahier R, Middlemiss D, Singh L, Tricklebank M, Wong E . In vivo labelling of the NMDA receptor channel complex by [3H]MK-801. Eur J Pharmacol. 1988; 158(3):279-82. DOI: 10.1016/0014-2999(88)90080-5. View

16.

Bergeron R, Meyer T, Coyle J, Greene R . Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci U S A. 1998; 95(26):15730-4. PMC: 28112. DOI: 10.1073/pnas.95.26.15730. View

17.

Fossat P, Turpin F, Sacchi S, Dulong J, Shi T, Rivet J . Glial D-serine gates NMDA receptors at excitatory synapses in prefrontal cortex. Cereb Cortex. 2011; 22(3):595-606. DOI: 10.1093/cercor/bhr130. View

18.

Lane H, Chang Y, Liu Y, Chiu C, Tsai G . Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry. 2005; 62(11):1196-204. DOI: 10.1001/archpsyc.62.11.1196. View

19.

Lane H, Liu Y, Huang C, Chang Y, Liau C, Perng C . Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry. 2007; 63(1):9-12. DOI: 10.1016/j.biopsych.2007.04.038. View

20.

Lane H, Lin C, Huang Y, Liao C, Chang Y, Tsai G . A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol. 2009; 13(4):451-60. DOI: 10.1017/S1461145709990939. View